Key result
Long-term statin exposure shows no link to increased cancer risk or mortality versus placebo.
Why the study?
The safety profile of statins regarding cancer risk in patients with long-term exposure was not completely clarified.
Does long-term statin exposure increase the risk of cancer occurrence or cancer mortality in patients?
Meta-Analysis (n=358,544)
Does long-term statin exposure increase the risk of cancer occurrence or cancer mortality in patients?
Long-term statin therapy (≥10 years) is not associated with an increased risk of cancer occurrence or cancer mortality, reinforcing their safety profile in cardiovascular prevention.
Supports long-term statin use without cancer concern; confirms and extends safety evidence to ≥10-year exposures.
INTRODUCTION: Statins are widely prescribed drugs with established efficacy in primary and secondary prevention of cardiovascular events. Although they are mostly well tolerated, several authors have been emphasizing that the statins' safety profile is not totally clarified especially when considering risk of cancer in patients with long-term exposure to statins. This meta-analysis was aimed at evaluating the risk of cancer in patients with prolonged exposure to statins. METHODS: Medline, Cochrane library, and clinicaltrials.gov were searched in order to identify studies with a minimum average follow-up of 10 years of exposure to statins and a cancer-related outcome reported. Relative risk (RR) of the primary outcomes and the combined effect was presented using a random-effects model. In the selected randomized control trials (RCT), statin exposure was compared with placebo, and in the selected observational studies, it was compared with no exposure to statins. RESULTS: We retrieved 1627 studies, of which 15 full-papers were included for final review, five RCT, two cohort studies (CSs), and eight case-control studies (CCs), representing a total of 358 544 patients. Five RCT, two cohort studies (CSs), and eight case-control studies (CCs). No significant differences were found regarding risk of cancer occurrence (RR = 1.08, 0.96-1.21) or cancer mortality (RR = 0.91, 0.80-1.04) due to long-term statin exposure. Regarding all-cause mortality, a protective effect was found (RR = 0.93, 0.90-0.97). CONCLUSIONS: According to available and published evidence, statins are not associated with an increased risk of cancer after prolonged exposure. These findings strengthen the role of statins in the primary and secondary prevention of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Craveiro et al. (2019) conducted a meta-analysis in Patients with long-term exposure to statins (n=358,544). Statins vs. Placebo or no exposure was evaluated on Risk of cancer occurrence (RR 1.08, 95% CI 0.96-1.21). Long-term statin exposure (≥10 years) was not associated with an increased risk of cancer occurrence (RR 1.08; 95% CI 0.96-1.21) or cancer mortality compared to placebo or no exposure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: